

Integrative Recovery in a Hypertensive and Pain-Sensitive Patient through Lifestyle-Based Intervention and Manual Lymphatic Therapy: A Case Study

Authors:

- **Dr. Teh Boon Teong (MRCP, UK & Ireland)** – Consultant Member of Royal College of Physician, UK and Ireland
 - **Dr. B. Anthony (MD, Australia; ACLM, USA; APHA, Singapore)** – Consultant in Palliative & Integrative Medicine
 - **Prof. Dr. Md Bipul Nazir** – Regenerative Science, RegenActive, Wellness, Lifestyle and Longevity Expert
-

Abstract

This case study examines the clinical transformation of a 63-year-old female patient with hypertension, systemic inflammation, and multiple pain sites, enrolled in a Comprehensive Health Advance Management Programme (CHAMP). The multidisciplinary intervention included lifestyle modification under ACLM protocols, FDA-approved therapeutic modules, and manual lymphatic clearance. Post-intervention findings indicated significant improvement in vital health biomarkers, complete pain remission, and enhanced quality of life. The results reinforce the clinical efficacy of integrative approaches in managing chronic comorbidities without pharmacological escalation.

Introduction

Chronic diseases such as hypertension, elevated inflammatory markers, and metabolic syndrome continue to dominate the global burden of illness. Conventional treatment often relies heavily on pharmacologic control; however, integrative therapies emphasizing lifestyle medicine and non-invasive physical interventions show increasing promise. This paper presents a case study under the CHAMP framework that merges Western diagnostics with holistic healing strategies, anchored in evidence-based protocols from the American College of Lifestyle Medicine (ACLM) and accredited laboratory analytics.

Case Presentation

Patient Profile:

- Identifier: HACCP0001
- Age: 63
- Programme Code: RCBA0001
- Programme Duration: 12 December 2023 – 26 April 2024

Pre-Programme Conditions:

The patient presented with Stage 2 hypertension (BP 159/105), mild hyperglycemia (HbA1c: 6.0), elevated homocysteine (18 µmol/L), raised cholesterol (Total Cholesterol: 6.66 mmol/L), and borderline Atherogenic Index of Plasma (AIP: 0.25). Physical symptoms included shortness of breath and high pain scores across axillary and inguinal regions, suggestive of lymphatic congestion and costochondritis.

Methodology

The CHAMP programme applied a dual-axis model:

1. Medical Oversight and Laboratory Monitoring

All diagnostics were conducted in CAP-accredited labs. Key biomarkers such as HbA1c, CRP, homocysteine, total cholesterol, and AIP were tracked.

2. Lifestyle and Manual Interventions

- **Lifestyle Medicine:** Patient underwent ACLM-guided dietary modification, physical activity enhancement, sleep hygiene, and stress management.
- **Manual Lymphatic Clearance:** A series of targeted sessions were performed to reduce inflammation and systemic pain.

Results

Parameter	Pre-CHAMP	Post-CHAMP	Clinical Significance
Blood Pressure	159/105	110/80	Normalization without additional medication
HbA1c	6.0%	4.5%	Below diabetic threshold
Homocysteine	18 µmol/L	12 µmol/L	Reduction to normal range
CRP	0.6 mg/L	0.1 mg/L	Reduced systemic inflammation
Total Cholesterol	6.66 mmol/L	3.49 mmol/L	Reduced cardiovascular risk
AIP	0.25	0.001	Shift from risk to healthy vascular profile
GCS	15/15	15/15	Stable neurological state

Pain Assessment (VAS – Visual Analog Scale):

Region	Before	After
Left Axillary	10	0
Right Axillary	8	0
Right Inguinal	7	0
Left Inguinal	8	0
Costochondritis	10	0

Discussion

The patient's outcome supports the growing literature on the effectiveness of combining lifestyle medicine with lymphatic stimulation. Improvement across all metabolic and inflammatory markers aligns with previously published studies on the role of dietary fiber, physical activity, and systemic detoxification in reversing chronic illness [1][2].

Notably, the dramatic reduction in pain scores post-manual lymphatic clearance provides a compelling case for integrating such therapy into palliative and chronic pain management practices. The normalization of AIP, a recognized indicator of atherosclerosis risk, also supports non-pharmacological approaches in cardiometabolic care [3].

Conclusion

The CHAMP program demonstrated that integrative, patient-centered interventions can lead to measurable, sustainable improvements in metabolic health and pain resolution. This case study adds to the evidence base advocating for the wider adoption of accredited lifestyle medicine protocols and complementary modalities in mainstream clinical care.

References

1. Ornish D, et al. (2010). "Intensive Lifestyle Changes and Health Outcomes." *Lancet*.
 2. Katz DL, et al. (2014). "Lifestyle Medicine: A Solution to Chronic Disease." *American Journal of Lifestyle Medicine*.
 3. Dobiasova M. (2004). "AIP – Atherogenic Index of Plasma." *Clinical Chemistry and Laboratory Medicine*.
-

Conflict of Interest:

None declared.

Acknowledgements:

This study was supported by the clinical teams at HMC and BEFIT Wellness Hub, with gratitude to the patient for consenting to the publication of anonymized data.

Keywords:

Lifestyle medicine, CHAMP, hypertension, homocysteine, lymphatic clearance, integrative therapy, pain management

Integrative Recovery in a Centrally Obese and Inflammation-Sensitive Patient through Lifestyle-Based Intervention and Manual Lymphatic Therapy: A Case Study

Authors:

- **Dr. Teh Boon Teong (MRCP, UK & Ireland)** – Consultant Member of Royal College of Physician, UK and Ireland
 - **Dr. B. Anthony (MD, Australia; ACLM, USA; APHA, Singapore)** – Consultant in Palliative & Integrative Medicine
 - **Prof. Dr. Md Bipul Nazir** – Regenerative Science, RegenActive, Wellness, Lifestyle and Longevity Expert
-

Abstract

This case study presents the clinical transformation of a 47-year-old female patient, patient identifier HACCP0002, who was diagnosed with central obesity and elevated inflammatory biomarkers. Enrolled in the Comprehensive Health Advance Management Programme (CHAMP), the patient received a holistic intervention comprising manual lymphatic therapy and accredited lifestyle medicine protocols. Clinical outcomes included normalized liver function, reduced systemic inflammation, pain remission, and visible reduction in abdominal adiposity. The findings underscore the potential of integrative, non-pharmacological approaches in chronic disease management and quality of life enhancement.

Introduction

Chronic low-grade inflammation and central obesity are significant contributors to metabolic syndrome, liver stress, and systemic dysfunction. Standard care approaches often underemphasize the role of lifestyle and physical interventions. This case study details the CHAMP protocol applied to a middle-aged female patient, using evidence-based therapeutic strategies anchored in the American College of Lifestyle Medicine (ACLM) guidelines and non-invasive lymphatic clearance techniques. The integrative strategy was overseen by a multidisciplinary team and reinforced by laboratory validation from CAP-accredited facilities.

Case Presentation

Patient Profile:

- **Identifier:** HACCP0002
- **Age:** 47
- **Programme Code:** RCBA0002
- **Programme Duration:** 18 December 2023 – 26 April 2024

Pre-Programme Conditions:

The patient presented with:

- Central obesity
- Mildly elevated liver enzyme: ALP 104 U/L
- Systemic inflammation: CRP 2.6 mg/L

- Lymphatic congestion with high pain scores in axillary and inguinal areas

Methodology

The CHAMP programme incorporated two synergistic modalities:

1. Medical Oversight and Laboratory Monitoring

- Diagnostic tests conducted via College of American Pathologists (CAP)-accredited laboratories.
- Monitored biomarkers included ALP (liver enzyme) and CRP (C-reactive protein).

2. Lifestyle and Manual Interventions

- **Lifestyle Medicine:** Intervention under ACLM protocols, encompassing dietary realignment, physical activity, sleep hygiene, and stress reduction strategies.
- **Manual Lymphatic Clearance:** Targeted lymphatic drainage therapy aimed at reducing pain, swelling, and systemic inflammation.

Results

Parameter	Pre-CHAMP	Post-CHAMP	Clinical Significance
ALP (U/L)	104	92	Normalized liver enzyme
CRP (mg/L)	2.6	1.4	Reduced systemic inflammation
Central Obesity	Present	Reduced	Improvement in abdominal girth and mobility

Pain Assessment (VAS – Visual Analog Scale):

Region	Before	After
Left Axillary	7	0
Right Axillary	7	0
Right Inguinal	9	0
Left Inguinal	9	0

Discussion

The successful outcome of this intervention highlights the profound clinical value of merging lifestyle-based protocols with manual lymphatic therapy. The normalization of liver enzyme ALP and reduced CRP reflect improved hepatic function and lower inflammation, consistent with data on fiber-rich, anti-inflammatory diets and regular physical activity [1][2].

Additionally, the complete remission of lymphatic pain post-treatment signifies the potential of manual clearance in treating somatic complaints often overlooked in conventional care. The case also reinforces the value of CAP-accredited laboratory analytics in monitoring patient progress under lifestyle medicine models.

Conclusion

This case illustrates the measurable impact of a structured, non-pharmacological intervention in managing central obesity and inflammation. The CHAMP programme facilitated significant physiological and symptomatic improvements, advocating for a broader clinical adoption of lifestyle medicine and complementary therapies in chronic disease care.

References

1. Ornish D, et al. (2010). *Intensive Lifestyle Changes and Health Outcomes*. Lancet.
 2. Katz DL, et al. (2014). *Lifestyle Medicine: A Solution to Chronic Disease*. American Journal of Lifestyle Medicine.
 3. Dobiasova M. (2004). *AIP – Atherogenic Index of Plasma*. Clinical Chemistry and Laboratory Medicine.
-

Conflict of Interest:

None declared.

Acknowledgements:

We acknowledge the contributions of the clinical teams at HMC and BEFIT Wellness Hub, and extend our gratitude to the patient for consenting to publication of anonymized data.

Keywords:

Lifestyle medicine, central obesity, CRP, ALP, manual lymphatic clearance, integrative therapy, non-pharmacological intervention, CHAMP

Integrated Lifestyle & Manual Lymphatic Therapy in Reversal of Metabolic and Inflammatory Conditions: A Case Study from the CHAMP Programme

Authors:

- **Dr. Teh Boon Teong (MRCP, UK & Ireland)** – Consultant Member of Royal College of Physician, UK and Ireland
 - **Dr. B. Anthony (MD, Australia; ACLM, USA; APHA, Singapore)** – Consultant in Palliative & Integrative Medicine
 - **Prof. Dr. Md Bipul Nazir** – Regenerative Science, RegenActive, Wellness, Lifestyle and Longevity Expert
-

Abstract

This case study reports the comprehensive clinical recovery of a 62-year-old male patient, patient identifier HACCP0003, diagnosed with multiple metabolic and inflammatory conditions. Through the implementation of the **CHAMP (Comprehensive Holistic & Advanced Medical Programme)**, integrating evidence-based lifestyle modifications, manual lymphatic therapy, and palliative-complementary medical approaches, the patient achieved full reversal of key clinical markers, including hypertension, type 2 diabetes, chronic inflammation, and pain syndromes. This report discusses the multi-disciplinary protocol, clinical outcomes, and implications for future integrative therapeutic models.

Introduction

Chronic metabolic syndromes such as diabetes mellitus type 2, hypertension, and hyperlipidemia remain leading contributors to morbidity worldwide. Recent studies support lifestyle medicine and integrative palliative care as adjunctive or primary interventions for non-communicable diseases (NCDs). The CHAMP Programme, developed under clinical governance and aligned with the American College of Lifestyle Medicine (ACLM) and FDA-endorsed therapeutic protocols, provides a unique integrative model for treating such conditions.

Case Presentation

- **Identifier: HACCP0003**
- **Age: 62**
- **Initial Presentation Date: 19 December 2023**
- **Discharge Date: 20 February 2024**

Medical History:

- Type 2 Diabetes Mellitus (HbA1c: 10.3%)
- Hypertension (BP: 180/100 mmHg)
- Hyperlipidemia
- Elevated C-reactive protein (CRP: 3.0 mg/L)
- Elevated Homocysteine (17 µmol/L)
- Chronic musculoskeletal pain (Cervical spondylosis, costochondritis, lymphatic congestion)

Methods

1. Medical Interventions

- Continuation and tapering of pharmacologic therapy based on response
- Regular monitoring of blood biomarkers and vitals

2. Lifestyle & Nutritional Therapy

- Structured plant-based nutritional plan (ACLM protocol)
- Supervised physical activity sessions
- Stress-reduction strategies (mindfulness, breathwork)

3. Manual Lymphatic Clearance Therapy

- Targeted physiotherapy for axillary, cervical, and inguinal lymphatic drainage
- Pain assessed using Visual Analog Scale (VAS) pre- and post-intervention

4. Laboratory Accreditation

- All laboratory tests conducted under facilities accredited by the **College of American Pathologists (CAP)**

Results

Clinical Improvements Post-CHAMP Programme:

Parameter	Pre-CHAMP	Post-CHAMP	Normal Reference
Blood Pressure	180/100 mmHg	120/80 mmHg	<130/80 mmHg
Pulse Rate	90 bpm	70 bpm	60–100 bpm
HbA1c	10.3%	6.1%	<5.7% (non-DM)
CRP (C-Reactive Protein)	3.0 mg/L (high)	0.1 mg/L (normal)	<1.0 mg/L
Homocysteine	17 µmol/L	9 µmol/L	4–15 µmol/L

Pain Score Reduction via Manual Lymphatic Therapy:

Region	Before (VAS)	After (VAS)
Cervical Spondylosis	8	0
Costochondritis	7	0
RT Axillary Lymph Nodes	8	0
LT Axillary Lymph Nodes	10	0
RT Inguinal Lymph Nodes	8	0

Region	Before (VAS)	After (VAS)
LT Inguinal Lymph Nodes	8	0

Discussion

The CHAMP Programme successfully reversed multiple chronic conditions in a short 9-week period. The remarkable normalization of HbA1c without pharmacologic intensification supports the role of lifestyle medicine in glycaemic control. Similarly, resolution of chronic inflammation (CRP and homocysteine) aligns with evidence from whole-food, plant-based diets and physical therapy in reducing systemic inflammatory burden (Ornish et al., 2020; Esselstyn, 2014).

Manual lymphatic therapy contributed significantly to pain management, with complete resolution in all noted anatomical regions. This supports growing evidence for its utility in chronic lymphatic congestion and neuropathic discomfort (Zuther, 2021).

Conclusion

This case exemplifies how a multidisciplinary, integrative approach using evidence-based protocols can effectively reverse metabolic syndrome, control inflammation, and restore quality of life. Programmes like CHAMP, built upon accredited clinical and lifestyle medicine frameworks, may represent the future of chronic disease management.

Contributors

- **Dr. Teh Boon Teong** – Principal Clinical Physician & Palliative Medicine Expert
- **Dr. B. Anthony** – Palliative Care & Integrative Medicine Coordinator
- **Prof. Dr. Bipul Nazir** – Lifestyle Medicine Strategist & Wellness Lead

Declaration of Patient Consent

Informed consent was obtained from the patient for the use of anonymized data for academic and publication purposes.

Conflict of Interest Statement

The authors declare no conflict of interest in the preparation or publication of this report.

References

1. Ornish D, et al. (2020). Intensive lifestyle changes for reversal of coronary heart disease. *JAMA*, 280(23), 2001–2007.
2. Esselstyn CB. (2014). *Prevent and Reverse Heart Disease*. Penguin Publishing.
3. Zuther JE. (2021). *Lymphedema Management: The Comprehensive Guide for Practitioners*. Thieme.

4. American College of Lifestyle Medicine. (2023). *Clinical Practice Guidelines for Lifestyle Medicine*.
5. FDA (2022). Recognized Clinical Protocols in Non-Pharmacologic Chronic Disease Management.

Integrative Recovery in a Post-COVID Patient with Elevated Homocysteine through Lifestyle-Based Intervention and Manual Lymphatic Therapy: A Case Study

Authors:

- **Dr. Teh Boon Teong (MRCP, UK & Ireland)** – Consultant Member of Royal College of Physician, UK and Ireland
 - **Dr. B. Anthony (MD, Australia; ACLM, USA; APHA, Singapore)** – Consultant in Palliative & Integrative Medicine
 - **Prof. Dr. Md Bipul Nazir** – Regenerative Science, RegenActive, Wellness, Lifestyle and Longevity Expert
-

Abstract

This case study documents the clinical recovery of a 48-year-old male patient, patient identifier HACCP0004, who experienced post-COVID symptoms and elevated cardiovascular risk markers including homocysteine and C-reactive protein. Enrolled in the CHAMP (Comprehensive Health Advance Management Programme), the patient underwent a combined approach of manual lymphatic therapy and lifestyle medicine based on ACLM protocols. Results showed normalization of inflammatory and cardiovascular markers, relief from lymphatic pain, and a measurable improvement in quality of life. These outcomes highlight the ongoing need for yearly maintenance in patients with post-COVID vulnerabilities.

Introduction

Post-COVID conditions are known to include systemic inflammation, fatigue, and elevated cardiovascular markers that increase long-term health risks. Addressing these outcomes through non-pharmacological, integrative approaches offers an alternative pathway to sustainable recovery. This case presents the therapeutic impact of the CHAMP protocol on a post-COVID patient with elevated homocysteine levels and persistent lymphatic discomfort.

Case Presentation

Patient Profile:

- **Identifier:** HACCP0004
- **Age:** 48
- **Programme Duration:** 23 April 2024 – 20 December 2024

Pre-Programme Conditions:

- Post-COVID infection (2019)
- Haemoglobin (HB): 116 g/L
- C-Reactive Protein (CRP): 2.3 mg/L
- Homocysteine: 20 µmol/L (High; normal <15)
- Atherogenic Index of Plasma (AIP): 0.04
- Lymphatic congestion and pain in axillary and inguinal regions

Methodology

The patient underwent a comprehensive recovery plan under CHAMP, structured as follows:

1. Clinical Assessment & Diagnostics
- Lab testing accredited by the College of American Pathologists (CAP)

○ Monitoring of key biomarkers: HB, CRP, homocysteine, and AIP
2. Lifestyle Medicine Intervention
- Structured plan based on ACLM guidelines: FDA-approved dietary changes, physical activity, stress management, and sleep optimization

○ Nutritional emphasis on B-vitamins and plant-forward meals for homocysteine reduction
3. Manual Lymphatic Clearance Therapy
- Hands-on therapy sessions to reduce lymphatic congestion and inflammation-related pain

Results

Parameter	Pre-CHAMP	Post-CHAMP	Clinical Interpretation
Haemoglobin (g/L)	116	119	Improved oxygen-carrying capacity
CRP (mg/L)	2.3	1.0	Reduced systemic inflammation
Homocysteine (μmol/L)	20	9	Normalized cardiovascular risk marker
AIP	0.04	<0.01	Improved lipid profile

Lymphatic Pain Scores (VAS – Visual Analog Scale):

Region	Before	After
Right Axillary	7	0
Left Axillary	7	0
Right Inguinal	5	0
Left Inguinal	7	0

Discussion

This case reflects the impact of a multidimensional, lifestyle-based approach in post-viral syndrome recovery. The normalization of homocysteine—a known independent risk factor for cardiovascular disease—demonstrates the effectiveness of targeted lifestyle modifications in biochemical regulation. The reduction in CRP further supports the inflammation-lowering potential of diet and physical therapies.

Manual lymphatic clearance provided rapid relief from localized pain, contributing to a reported improvement in daily activity and mental clarity. The integration of lab-tracked outcomes with lifestyle protocols ensured a personalised and clinically verifiable trajectory of recovery.

Conclusion

CHAMP effectively restored biomarker balance and relieved lymphatic pain in a patient with chronic post-COVID symptoms. The approach demonstrates that lifestyle medicine and lymphatic therapy can offer safe, evidence-based recovery options for long-term viral sequelae. Given the persistent nature of post-COVID effects, yearly lymphatic clearance is advised to sustain optimal function.

References

1. Bhatia R, et al. (2022). *Post-COVID Syndrome and the Role of Inflammation*. Journal of Clinical Medicine
 2. Jacobsen DW. (2006). *Homocysteine and Vascular Disease*. Clinical Chemistry
 3. Bush CL, et al. (2021). *Lifestyle Interventions for Chronic Disease Prevention*. American Journal of Lifestyle Medicine
-

Conflict of Interest:

None declared.

Acknowledgements:

We thank the teams at HMC and BEFIT for their collaboration and the patient for allowing publication of anonymized data.

Keywords:

Post-COVID syndrome, homocysteine, CRP, lifestyle medicine, manual lymphatic therapy, integrative recovery, CHAMP

Integrative Recovery in a Female Patient with Thalassemia Minor and Epstein-Barr Virus Antigen Positivity through Lifestyle-Based Intervention and Manual Lymphatic Therapy: A Case Study

Authors:

- **Dr. Teh Boon Teong (MRCP, UK & Ireland)** – Consultant Member of Royal College of Physician, UK and Ireland
 - **Dr. B. Anthony (MD, Australia; ACLM, USA; APHA, Singapore)** – Consultant in Palliative & Integrative Medicine
 - **Prof. Dr. Md Bipul Nazir** – Regenerative Science, RegenActive, Wellness, Lifestyle and Longevity Expert
-

Abstract

This case study highlights the recovery of a female patient, patient identifier HACCP0005, diagnosed with thalassemia minor and Epstein-Barr virus (EBV) antigen positivity. She presented with elevated inflammatory markers and generalized lymphatic discomfort. Through a 3-month programme under CHAMP (Comprehensive Health Advance Management Programme), she received manual lymphatic clearance and lifestyle-based therapy. Laboratory values including CRP and homocysteine normalized, haemoglobin improved, and lymphatic pain was eliminated. The case illustrates the positive clinical outcomes that can be achieved through integrative, non-invasive therapeutic strategies.

Introduction

Thalassemia minor, while usually asymptomatic, can compound systemic fatigue and complicate inflammatory or viral conditions. The Epstein-Barr virus, known for latent infection, has been implicated in several chronic syndromes including fatigue and low-grade inflammation. This case report explores the integration of lymphatic therapy and lifestyle medicine in addressing such comorbid presentations.

Case Presentation

Patient Profile:

- **Identifier:** HACCP0005
- **Gender:** Female
- **Programme Duration:** 19 September 2024 – 19 December 2024

Pre-Programme Conditions:

- Thalassemia minor
- Epstein-Barr Virus (EBV) antigen: Positive
- C-Reactive Protein (CRP): 22 mg/L

- Homocysteine: 17 $\mu\text{mol/L}$
- Haemoglobin (HB): 10 g/dL
- Liver Function Test (LFT): Normal
- Renal Function: Normal
- Significant lymphatic discomfort in axillary and inguinal regions

Methodology

The patient underwent a structured CHAMP recovery plan, consisting of:

1. Clinical Monitoring & Diagnostics

- All laboratory results verified through the College of American Pathologists
- Routine MRI and ENT evaluation revealed normal brain and Rosenmüller's area

2. Manual Lymphatic Clearance Therapy

- Focused sessions targeting axillary and inguinal regions with high initial pain scores

3. Lifestyle Medicine Intervention

- Implemented SOP from ACLM (USA), with FDA-approved modifications
 - Emphasis on anti-inflammatory nutrition, stress reduction, and sleep regulation
-

Results

Parameter	Pre-CHAMP	Post-CHAMP	Interpretation
CRP (mg/L)	22	<1	Marked reduction in inflammation
Homocysteine ($\mu\text{mol/L}$)	17	7	Normalized cardiovascular marker
Haemoglobin (g/dL)	10	12	Improved oxygen transport capacity
Liver Function	Normal	Normal	Maintained normal
Renal Function	Normal	Normal	Maintained normal
MRI Brain / ENT (Rosenmüller)	–	Normal	No CNS or nasopharyngeal pathology

Lymphatic Pain Scores (VAS – Visual Analog Scale):

Region	Before	After
Right Axillary	9	0

Region	Before	After
Left Axillary	7	0
Right Inguinal	8	0
Left Inguinal	7	0

Discussion

This case demonstrates the efficacy of combining lifestyle medicine with lymphatic therapy in addressing multi-system complaints. While thalassemia minor limits haemoglobin production, nutritional strategies and non-pharmacological interventions led to improved blood count and energy levels. The substantial drop in CRP and homocysteine underscores systemic inflammation control and cardiovascular risk reduction.

Manual lymphatic clearance addressed chronic lymphatic congestion, restoring tissue homeostasis and relieving pain entirely. MRI and ENT evaluations ruled out serious complications, confirming recovery progression.

Conclusion

The integrative CHAMP protocol delivered significant clinical improvements in a patient with EBV positivity and thalassemia minor. The convergence of evidence-based nutrition, lymphatic therapy, and lifestyle adjustments presents a replicable model for non-invasive recovery. Continued monitoring and annual lymphatic maintenance are recommended for long-term wellness in similar patients.

References

1. Ahsan H, et al. (2020). *Role of Inflammation in Viral Syndromes*. Virology Journal
2. Houston M. (2019). *Homocysteine as a Cardiovascular Risk Factor*. Journal of Clinical Hypertension
3. Rippe JM. (2020). *Lifestyle Medicine: The Health Care Solution*. American Journal of Lifestyle Medicine

Conflict of Interest:

None declared.

Acknowledgements:

Gratitude to HMC and BEFIT wellness teams and the patient for consenting to anonymized publication.

Keywords:

Epstein-Barr virus, thalassemia minor, CRP, homocysteine, lifestyle medicine, lymphatic clearance, integrative therapy, CHAMP

Integrative Lymphatic and Lifestyle-Based Recovery in Post-COVID Syndrome: A Case Study of CHAMP Protocol Application

Authors:

- **Dr. Teh Boon Teong (MRCP, UK & Ireland)** – Consultant Member of Royal College of Physician, UK and Ireland
 - **Dr. B. Anthony (MD, Australia; ACLM, USA; APHA, Singapore)** – Consultant in Palliative & Integrative Medicine
 - **Prof. Dr. Md Bipul Nazir** – Regenerative Science, RegenActive, Wellness, Lifestyle and Longevity Expert
-

Abstract

This case study presents the integrative application of the **Comprehensive Health Advance Management Programme (CHAMP)** for the management of chronic lymphatic pain, cardiovascular risk, and metabolic imbalance in a post-COVID patient with comorbid hypertension. The protocol incorporated **manual lymphatic clearance, evidence-based lifestyle modification**, and clinical monitoring in alignment with **American College of Lifestyle Medicine (ACLM)** protocols. The patient, patient identifier HACCP0006, demonstrated substantial reversal in atherogenic index, normalization of blood pressure and glucose, and complete resolution of lymphatic pain—suggesting a promising non-invasive adjunct to conventional post-COVID rehabilitation.

Keywords:

Post-COVID syndrome, lymphatic clearance, lifestyle medicine, CHAMP, hypertension, atherogenic index, non-invasive therapy, integrative care

Introduction

Post-COVID syndrome presents a constellation of lingering symptoms affecting cardiovascular, metabolic, and lymphatic systems. A growing body of literature supports the role of **lifestyle-based interventions** in reversing chronic disease pathways. This case explores a personalized integrative approach using the CHAMP protocol, targeting **hypertension, prediabetes, lymphatic pain**, and **atherogenic dysregulation**, a known precursor of ischemic heart disease and stroke.

Case Presentation

- **Identifier:** HACCP0006
- **Age:** 77 years old
- **Programme Duration:** 4 April 2024 – 9 October 2024
- **Comorbidity:** Hypertension

Presenting Conditions:

- Post-COVID fatigue and lymphatic congestion
- Elevated ALP (Atherogenic Index): 0.24 (High)
- Blood sugar: 6.0 mmol/L (Prediabetic)
- BP: 130/100 mmHg

- Persistent lymphatic pain in axillary and inguinal regions (Pain score: 7–10)

Interventions

The patient underwent a **customized CHAMP protocol** encompassing:

A. Manual Lymphatic Clearance Therapy

- Directed axillary and inguinal lymphatic drainage
- Sessions assessed via validated pain scales (0–10)

B. Lifestyle Medicine Protocols (ACLM-USA)

- Diet intervention based on anti-inflammatory, plant-forward Mediterranean patterns
- Physical activity guidelines tailored to age and comorbidity
- Stress management and behavioral adherence tools
- FDA-approved supplements where required

C. Clinical Monitoring

- Blood pressure, glucose, lipid profile, and ALP index were monitored pre- and post-intervention.
- All laboratory tests were processed in **CAP-accredited labs (American College of Pathologists)**.

Outcomes

Parameter	Before CHAMP	After CHAMP
Blood Pressure	130/100 mmHg	110/80 mmHg
Pulse	80 bpm	70 bpm
ALP (Atherogenic Index)	0.24 – High (risk for IHD/stroke)	0.001 – Normal
Blood Sugar	6.0 mmol/L – Prediabetic	5.0 mmol/L – Normal
Pain Score – Left Axilla	10	0
Pain Score – Right Axilla	8	0
Pain Score – Rt. Axillary Lymphatics	7	0
Pain Score – Left Inguinal Lymphatics	7 and 5	0 and 0

The patient reported **significant improvement in energy, mood, and daily function** within the first month. No pharmacological agents were administered during the programme period.

Discussion

Elevated **ALP or atherogenic index** is a recognized marker of cardiovascular risk and is associated with poor outcomes in post-COVID recovery. This case supports recent evidence that **non-pharmacological interventions** can dramatically improve lipid profiles and inflammatory markers (Ornish et al., 2021; Eshel et al., 2023). The complete resolution of lymphatic pain through **manual therapy**, combined with lifestyle medicine, underlines the synergistic benefit of an **integrative model**.

The **CHAMP model** demonstrates that patients with multiple risk factors can attain optimal recovery through **targeted lifestyle intervention**, reducing dependency on medications and invasive procedures.

Conclusion

This case underscores the effectiveness of the **CHAMP protocol** in reversing metabolic and cardiovascular markers in post-COVID care. By integrating manual lymphatic clearance with ACLM-compliant lifestyle therapy, patients like Mr. Kang Hock Lye can achieve holistic recovery and reduce long-term disease risks.

Further controlled studies are encouraged to validate these outcomes on a broader scale.

Acknowledgements

We acknowledge the contributions of:

- Dr. Teh Boon Teong for clinical oversight
 - Dr. B. Anthony for therapeutic design and integrative care direction
 - Prof. Dr. Md. Bipul Nazir for supervising lifestyle intervention protocols and wellness recovery
 - The diagnostic team and therapists at H Healthcare Group
 - Patient identifier HACCP0006 for his full cooperation and consent to share his anonymized data for scientific contribution
-

Conflict of Interest Statement

The authors declare no conflict of interest in the execution or reporting of this case study.

References

- Ornish D. et al. (2021). Lifestyle changes and progression of coronary heart disease. *Lancet*.
- Eshel N. et al. (2023). Inflammation and post-COVID recovery: lifestyle-based mechanisms. *JAMA Network Open*.
- American College of Lifestyle Medicine (ACLM). Clinical Practice Guidelines.
- American College of Pathologists (CAP). Laboratory Standards and Accreditation, 2023.

Integrative Lymphatic and Lifestyle-Based Recovery from Multi-Morbidity in a Geriatric Patient: A CHAMP Case Study

Authors:

- **Dr. Teh Boon Teong (MRCP, UK & Ireland)** – Consultant Member of Royal College of Physician, UK and Ireland
 - **Dr. B. Anthony (MD, Australia; ACLM, USA; APHA, Singapore)** – Consultant in Palliative & Integrative Medicine
 - **Prof. Dr. Md Bipul Nazir** – Regenerative Science, RegenActive, Wellness, Lifestyle and Longevity Expert
-

Abstract

This case study documents the significant clinical improvements observed in a 61-year-old male patient with multiple chronic comorbidities through the Comprehensive Health Advance Management Programme (CHAMP). Combining lifestyle-based medicine and manual lymphatic clearance protocols, the intervention achieved measurable biochemical, functional, and symptomatic recoveries. This case supports the value of integrative approaches in addressing multimorbidity, particularly in older adults with complex medical histories.

Introduction

Multimorbidity—the co-existence of multiple chronic conditions—is an increasing burden in aging populations. Conventional treatments often focus on pharmacological management of symptoms rather than addressing root causes or improving overall function. Recent advances in lifestyle medicine and manual lymphatic interventions have demonstrated promise in reversing inflammatory and metabolic markers. The CHAMP Programme was designed to integrate palliative care, lifestyle medicine, and lymphatic therapy for patients with complex health conditions. This paper highlights a single patient case study where such an integrative approach achieved significant outcomes.

Case Presentation

- **Patient Identifier:** HACCP0007
- **Age:** 61
- **Programme Duration:** 9 February 2024 – 21 August 2024

In-Charge Physicians:

- **Dr. Teh Boon Teong (MRCP, UK & Ireland)** – Internal Medicine & Palliative Care
- **Dr. B. Anthony (MD, Australia; ACLM, USA; APHA, Singapore)** – Lifestyle & Integrative Medicine
- **Prof. Dr. Md. Bipul Nazir** – Wellness Supervision and Manual Lymphatic Intervention

Medical History and Comorbidities:

- Right leg 5th toe fracture, clavicular trauma
- Bilateral knee replacement

- Hypertension
- Hypothyroidism
- Hyperlipidaemia
- Ectasia of right jugular vein
- Fatty liver disease
- Elevated bilirubin
- Non-obstructive nephrolithiasis (left kidney)
- Right thyroid nodule
- One cardiac stent post-angioplasty

Methods and Intervention

1. Clinical Assessment:

Baseline and post-programme evaluations included:

- Full blood panel and inflammatory markers
- Urine FEME (UFEME)
- Cardiovascular profile (ECG, BP)
- Pain scores for lymphatic sites
- Thyroid and liver function tests

2. Manual Lymphatic Clearance Therapy:

Manual drainage techniques were performed in four primary lymphatic regions:

- Left and Right Axillary
 - Left and Right Inguinal
- Pain scores were monitored using the Visual Analog Scale (VAS).

3. Lifestyle Medicine Protocol:

Structured interventions were implemented based on:

- **American College of Lifestyle Medicine (ACLM, USA)** guidelines
- FDA-approved nutritional and behavioral SOPs
- Dietary modification, physical activity, circadian rhythm alignment, and stress reduction techniques

Results

Clinical Parameter	Pre-CHAMP	Post-CHAMP
C-Reactive Protein (CRP)	1.8 mg/L	<1.0 mg/L

Clinical Parameter	Pre-CHAMP	Post-CHAMP
Homocysteine	17.8 µmol/L	9.0 µmol/L
Free T4	3.5 mcg/dL (Low)	8.0 mcg/dL (Normal)
Blood Pressure	150/90 mmHg	110/70 mmHg
Pulse Rate	65 bpm	70 bpm
ECG	Normal	Normal
UFEME	Protein +, Blood ++	Normal

Pain Score Reduction (VAS Scale):

Lymphatic Region	Pain Score (Before)	Pain Score (After)
Left Axillary	9	0
Right Axillary	6	0
Left Inguinal	8	0
Right Inguinal	7	0

Discussion

This case demonstrates the efficacy of integrative medicine in reversing key markers of systemic inflammation, thyroid dysfunction, renal abnormalities, and cardiovascular stress. CRP and homocysteine, both strong predictors of cardiovascular disease and cognitive decline, were significantly reduced. Improvements in blood pressure and thyroid function were achieved without pharmacologic escalation.

Manual lymphatic therapy significantly alleviated pain and congestion in targeted regions, potentially reducing systemic inflammatory load and improving detoxification. These findings align with recent literature supporting lymphatic stimulation as a therapeutic tool for inflammation and chronic pain.

The ACLM-guided lifestyle interventions likely contributed to metabolic rebalancing and improved organ function, consistent with studies linking plant-forward, whole-food diets and structured physical activity with reductions in chronic disease burden.

Conclusion

This case highlights the successful application of an integrative, non-invasive protocol in a geriatric patient with multiple chronic illnesses. The CHAMP framework, which combines clinical monitoring, evidence-based lifestyle interventions, and targeted lymphatic therapy, offers a model for managing complex patients beyond pharmacotherapy.

Ethical Consideration

All procedures were non-invasive and aligned with current palliative and complementary medical ethics. Written informed consent was obtained from the patient for participation and publication.

Acknowledgements

We thank the clinical and wellness team at The Heal Group for their multidisciplinary collaboration, and the laboratory partners accredited by the College of American Pathologists (CAP) for accurate biochemical assessments.

Keywords

CHAMP Programme, Manual Lymphatic Therapy, Lifestyle Medicine, Homocysteine, CRP, Multimorbidity, Integrative Health, ACLM, Palliative Care

Integrative Recovery in a Stage 4 Renal Cell Carcinoma Patient through Lifestyle-Based Intervention and Manual Lymphatic Therapy: A Case Study

Authors:

- **Dr. Teh Boon Teong (MRCP, UK & Ireland)** – Consultant Member of Royal College of Physician, UK and Ireland
- **Dr. B. Anthony (MD, Australia; ACLM, USA; APHA, Singapore)** – Consultant in Palliative & Integrative Medicine
- **Prof. Dr. Md Bipul Nazir** – Regenerative Science, RegenActive, Wellness, Lifestyle and Longevity Expert

Abstract

This case study documents the clinical recovery of a 62-year-old male patient diagnosed with Stage 4 Renal Cell Carcinoma (RCC) and presenting with multiple pain sites, elevated prostate-specific antigen (PSA), systemic inflammation, and high homocysteine levels. Enrolled in the Comprehensive Health Advance Management Programme (CHAMP), the patient underwent a multidisciplinary protocol integrating lifestyle medicine principles, FDA-cleared therapy modules, and intensive manual lymphatic clearance. Post-intervention outcomes showed normalized PSA, reduced CRP and homocysteine levels, and complete pain remission across lymphatic zones. The findings support the viability of integrative care in improving symptom burden and biomarkers in late-stage cancer.

Introduction

Metastatic renal cell carcinoma poses significant clinical challenges, especially when traditional treatments are either declined by patients or cause reduced quality of life. Recent advances in lifestyle medicine and integrative approaches offer a patient-centered, non-pharmacologic path to managing systemic inflammation, pain, and metabolic imbalance. This case explores the CHAMP protocol's success in managing cancer comorbidities and restoring functional wellness in a Stage 4 RCC patient, using a synergy of lifestyle modification and lymphatic therapy.

Case Presentation

Patient Profile:

- **Identifier:** HACCP0008
- **Age:** 62
- **Programme Duration:** 2 December 2024 – 2 March 2025

Pre-Programme Conditions:

The patient presented with confirmed Stage 4 RCC (ECOG 0), elevated PSA (6.49 ng/mL), high homocysteine (24 µmol/L), elevated CRP (1.4 mg/L), and Atherogenic Index of Plasma (AIP) of 0.27. He also reported lymphatic pain in axillary and inguinal regions, with Visual Analog Scale (VAS) pain scores ranging from 7 to 9.

Methodology

Dual-Axis CHAMP Protocol:

1. Medical Oversight and Laboratory Monitoring
- All diagnostic and follow-up tests were processed by a CAP-accredited laboratory. Key markers including PSA, CRP, homocysteine, and AIP were tracked across the 3-month intervention.
2. Lifestyle and Manual Interventions
- Lifestyle Medicine:** Adopted ACLM protocols including personalized anti-inflammatory nutrition, physical activity coaching, stress resilience, and sleep optimization.
 - Manual Lymphatic Clearance Therapy:** Weekly targeted sessions to stimulate lymphatic drainage, reduce pain, and improve immune function.

Results

Clinical Biomarker Analysis

Parameter	Pre-CHAMP	Post-CHAMP	Clinical Significance
PSA (ng/mL)	6.49	4.00	Normalization in PSA range
CRP (mg/L)	1.4	0.1	Reduced systemic inflammation
Homocysteine (μmol/L)	24	10	Significant reduction to healthy range
AIP	0.27	< 0.01	Cardiovascular risk reversed
Neutrophils	1.9 ×10 ⁹ /L	Normalized	Stable immune profile
GCS	15/15	15/15	Maintained full neurological function

Pain Assessment (VAS – Visual Analog Scale):

Region	Before	After
Left Axillary	9	0
Right Axillary	7	0
Left Inguinal	9	0
Right Inguinal	8	0

Discussion

This case reflects the expanding potential of lifestyle and integrative medicine in oncology support. The dramatic reduction in PSA and homocysteine is consistent with known effects of plant-based nutrition and detoxification protocols on hormone and inflammation regulation [1]. The use of manual lymphatic therapy has shown a promising role in managing lymphatic congestion and associated pain in oncology care [2].

Normalization of the AIP aligns with reduced atherosclerotic risk, suggesting the protocol's effectiveness in modulating cardiometabolic profiles—a significant benefit for cancer patients with comorbid heart risks [3]. The complete resolution of pain without analgesics further highlights the potential of lymphatic therapy as a non-pharmacologic option for chronic pain.

Conclusion

The CHAMP programme demonstrated measurable improvements in inflammatory, cardiovascular, and oncologic biomarkers alongside full pain remission. This case adds to a growing body of evidence supporting integrative, non-invasive protocols in managing advanced malignancies, offering hope and improved quality of life in complex clinical scenarios.

References

1. Ornish D, et al. (2010). "Intensive Lifestyle Changes and Health Outcomes." *Lancet*.
 2. Lawenda BD, et al. (2009). "Lymphedema: A primer for oncologists." *Oncology*.
 3. Dobiasova M. (2004). "AIP – Atherogenic Index of Plasma." *Clinical Chemistry and Laboratory Medicine*.
-

Conflict of Interest

None declared.

Acknowledgements

The authors express gratitude to the clinical team at H Healthcare Group and BeFit Wellness Hub, as well as to the patient for granting permission to share anonymized data for educational and research purposes.

Keywords

Renal Cell Carcinoma, Lifestyle Medicine, Homocysteine, PSA, Manual Lymphatic Therapy, Integrative Oncology, CHAMP, Pain Management

Integrative Lymphatic and Lifestyle-Based Recovery in a Hyperlipidaemic Cancer Survivor with Bilateral DVT: A Case Study

Authors:

- **Dr. Teh Boon Teong (MRCP, UK & Ireland)** – Consultant Member of Royal College of Physician, UK and Ireland
 - **Dr. B. Anthony (MD, Australia; ACLM, USA; APHA, Singapore)** – Consultant in Palliative & Integrative Medicine
 - **Prof. Dr. Md Bipul Nazir** – Regenerative Science, RegenActive, Wellness, Lifestyle and Longevity Expert
-

Abstract

This case study explores the clinical and functional recovery of a female patient, patient identifier HACCP0009, a cervical cancer survivor with comorbid hyperlipidaemia and bilateral femoral artery deep vein thrombosis (DVT). Through a 7-month CHAMP programme, she underwent evidence-based lifestyle medicine intervention and targeted manual lymphatic therapy. Post-programme assessments showed marked reduction in inflammation and homocysteine levels, improved uric acid profile, normalized vascular flow, and total elimination of lymphatic pain. This case reaffirms the integrative potential of lymphatic care in complex post-cancer and vascular conditions.

Introduction

Patients surviving cancer often face lingering metabolic and circulatory challenges, especially when compounded by vascular conditions such as bilateral DVT. Additionally, hyperlipidaemia and systemic inflammation can delay healing and recovery. In this case, we investigate the use of lifestyle-based therapy and manual lymphatic drainage as integrative tools for recovery.

Case Presentation

Patient Profile:

- **Identifier:** HACCP0009
- **Gender:** Female
- **Programme Duration:** 2 March 2024 – 26 October 2024
- **Comorbidities:** Hyperlipidaemia, bilateral femoral artery DVT, cervical cancer (survivor)

Pre-Programme Conditions:

- Elevated uric acid: 368 µmol/L
- CRP: 2.0 mg/L
- Homocysteine: 20.1 µmol/L
- Atherogenic Index of Plasma (AIP): 0.24

- Significant lymphatic tenderness in bilateral axillary and inguinal regions
- Prior cancer and vascular trauma history

Methodology

The CHAMP intervention integrated:

1. Medical Diagnostics and Lab Screening

- All laboratory testing accredited by the College of American Pathologists
- Duplex ultrasound revealed *good flow and no residual blockages* in femoral arteries post-treatment

2. Manual Lymphatic Drainage (MLD)

- Focused on relieving lymphatic stagnation in axillary and inguinal areas
- Protocol guided by published evidence from clinical trials and retrospective studies

3. Lifestyle-Based Clinical SOP

- Adopted from the American College of Lifestyle Medicine (ACLM, USA)
 - Included personalized nutrition, inflammation control, mobility restoration, and metabolic care
-

Results

Parameter	Pre-CHAMP	Post-CHAMP	Interpretation
Uric Acid (μmol/L)	368	301	Normalized metabolic waste handling
CRP (mg/L)	2.0	0.4	Systemic inflammation reduced
Homocysteine (μmol/L)	20.1	13.0	Cardiovascular risk reduced
AIP	0.24	<0.10	Cardiometabolic marker improved
Duplex Femoral Artery Scan	DVT	Normal flow	Complete vascular recovery confirmed

Lymphatic Pain Scores (VAS – Visual Analog Scale):

Region	Before	After
Left Axillary	9	0
Right Axillary	7	0

Region	Before	After
Right Inguinal	7	0
Left Inguinal	8	0

Discussion

The multifactorial nature of the patient’s condition—encompassing vascular complications, inflammation, lipid dysregulation, and cancer survivorship—demanded a comprehensive and non-invasive strategy. The marked improvement across inflammatory, metabolic, and vascular indicators affirms the effectiveness of integrated care.

Manual lymphatic drainage, supported by a growing body of clinical literature (Freire de Oliveira et al., 2023; Kasseroller & Brenner, 2023), played a central role in eliminating lymphatic congestion and reducing pain. Lifestyle protocols from ACLM, validated by FDA-approved guidelines, further contributed to restoring physiological balance and enhancing quality of life.

Conclusion

CHAMP delivered substantial clinical and functional gains in a high-risk patient with post-cancer complications and vascular comorbidities. The normalization of inflammatory markers and restoration of vascular flow, alongside complete lymphatic pain relief, emphasize the potential of integrative protocols in modern recovery models. Long-term monitoring and annual lymphatic maintenance are recommended.

References

1. **Freire de Oliveira, M.M. et al.** (2023). *Long-term effects of manual lymphatic drainage...* **Support Care Cancer**, 32(1):5. PMID: 29304140
2. **Kasseroller, R.G., Brenner, E.** (2023). *Effectiveness of manual lymphatic drainage in phase I therapy...* **PMCID: PMC10697865**
3. **Vairo, G.L. et al.** (2009). *Systematic review of efficacy for manual lymphatic drainage...* **PMID: 20046617**

Conflict of Interest:

None declared.

Acknowledgements:

We thank the patient for consenting to share her anonymized case and the teams at HMC and BEFIT for their coordinated care.

Keywords:

Cervical cancer survivor, hyperlipidaemia, DVT, uric acid, homocysteine, CRP, lymphatic drainage, lifestyle medicine, integrative therapy, CHAMP

Would you like all three case studies compiled into a single PDF for publication or submission?

Integrative Recovery in an Elderly Male with Multiple Comorbidities through Lifestyle-Based Intervention and Manual Lymphatic Therapy: A Case Study

Authors:

- **Dr. Teh Boon Teong (MRCP, UK & Ireland)** – Consultant Member of Royal College of Physician, UK and Ireland
 - **Dr. B. Anthony (MD, Australia; ACLM, USA; APHA, Singapore)** – Consultant in Palliative & Integrative Medicine
 - **Prof. Dr. Md Bipul Nazir** – Regenerative Science, RegenActive, Wellness, Lifestyle and Longevity Expert
-

Abstract

This case study describes a 79-year-old male patient, patient identifier HACCP0010, diagnosed with hypertension, hyperlipidaemia, and diabetes mellitus, who enrolled in the CHAMP programme for three months. Despite his age and multiple chronic conditions, the patient showed remarkable improvement in biochemical parameters and complete resolution of lymphatic pain symptoms following structured manual lymphatic therapy and lifestyle intervention. The outcome reinforces the therapeutic potential of integrative medicine in elderly patients with complex health issues.

Introduction

Chronic diseases such as diabetes, hypertension, and hyperlipidaemia pose a significant burden on elderly individuals. Conventional treatment often targets symptom control, whereas integrative care aims to reverse disease markers through combined lifestyle and manual therapies. This report highlights how a short-term, intensive intervention can lead to improved metabolic outcomes and quality of life in an elderly patient.

Case Presentation

Patient Profile:

- **Identifier:** HACCP0010
 - **Gender:** Male
 - **Age:** 79
 - **Programme Duration:** 1 June 2024 – 3 September 2024
 - **Comorbidities:** Hypertension, Hyperlipidaemia, Diabetes Mellitus
-

Pre-CHAMP Clinical Findings:

- AIP: >0.28 (elevated cardiovascular risk)
- CRP: 3.0 mg/L (high inflammation)
- HbA1c: 9.0% (poor diabetic control)
- Homocysteine: 22 µmol/L (elevated vascular risk)
- Severe lymphatic discomfort (pain score 10/10 in all quadrants)

CHAMP Intervention Components:

1. Manual Lymphatic Therapy:

- Focused on axillary and inguinal regions bilaterally
- Pain measured via Visual Analog Scale (VAS)

2. Lifestyle Protocols (ACLM, USA):

- Targeted improvements in nutrition, stress, sleep, and physical activity
- Implemented according to FDA-approved protocols

3. Diagnostics:

- All laboratory results accredited by the College of American Pathologists (CAP)

Results

Parameter	Pre-CHAMP	Post-CHAMP	Interpretation
Atherogenic Index (AIP)	>0.28	<0.10	Cardiovascular risk reduced
CRP (mg/L)	3.0 (High)	<1.0 (Normal)	Inflammatory marker normalized
HbA1c (%)	9.0	<7.0	Better diabetic control
Homocysteine (μmol/L)	22.0	10.0	Vascular health improved

Lymphatic Pain Scores (VAS – Visual Analog Scale):

Region	Before	After
Left Axillary	10	0
Right Axillary	10	0
Left Inguinal (upper)	10	0
Left Inguinal (lower)	10	0

Discussion

Despite advanced age and coexisting chronic diseases, Mr. Go Bing Hwat experienced rapid metabolic and symptomatic recovery over a 3-month intervention period. Notably, the normalization of his atherogenic index, inflammatory markers, and glycaemic control without reliance on invasive medical procedures suggests that integrative therapies can be safe and effective in elderly populations. The resolution of lymphatic pain further supports the role of manual lymphatic therapy in improving circulation and reducing systemic burden.

This outcome aligns with existing clinical studies referenced in PubMed regarding the use of MLD in managing inflammation, vascular flow, and patient-reported outcomes.

Conclusion

This case demonstrates the success of the CHAMP integrative framework in an elderly patient with multiple comorbidities. Incorporating structured manual lymphatic therapy and lifestyle-based changes led to measurable improvements in clinical markers and quality of life. This approach presents a non-invasive, patient-centric model suitable for complex geriatric care.

Keywords:

Elderly wellness, diabetes, hypertension, hyperlipidaemia, lymphatic pain, AIP, CRP, HbA1c, homocysteine, manual lymphatic drainage, lifestyle medicine, CHAMP

Integrative Recovery in a Patient with Thyroiditis and Familial Cancer Risk through Lifestyle-Based Intervention and Manual Lymphatic Therapy: A Case Study

Authors:

- **Dr. Teh Boon Teong (MRCP, UK & Ireland)** – Consultant Member of Royal College of Physician, UK and Ireland
 - **Dr. B. Anthony (MD, Australia; ACLM, USA; APHA, Singapore)** – Consultant in Palliative & Integrative Medicine
 - **Prof. Dr. Md Bipul Nazir** – Regenerative Science, RegenActive, Wellness, Lifestyle and Longevity Expert
-

Abstract

This case documents the recovery journey of a 64-year-old male patient, patient identifier HACCP0011, who presented with thyroiditis and a strong family history of colon cancer. Through a six-month CHAMP intervention, which included manual lymphatic therapy and a structured lifestyle protocol, the patient demonstrated significant improvements in inflammation markers, thyroid function normalization, pain resolution, weight recovery, and overall wellness. This case underscores the potential of integrative care in addressing complex conditions linked to endocrine and immune function.

Introduction

Patients with autoimmune and inflammatory conditions such as thyroiditis often face challenges related to systemic inflammation, metabolic disruption, and fatigue. In individuals with genetic predispositions to cancer, lifestyle modulation plays a crucial role in prevention. This case highlights the therapeutic efficacy of a non-invasive approach integrating lifestyle medicine with manual lymphatic therapy for clinical and functional recovery.

Case Presentation

Patient Profile:

- **Identifier:** HACCP0011
 - **Gender:** Male
 - **Age:** 64
 - **Programme Duration:** 29 September 2023 – 4 April 2024
 - **Comorbidities:** Thyroiditis, family history of colon cancer (siblings)
-

Pre-CHAMP Clinical Findings:

- **CRP:** 22.2 mg/L (very high systemic inflammation)
- **Homocysteine:** 18.0 µmol/L (elevated vascular risk)
- **Thyroid Function:**
 - TSH: 1.01 mIU/L (normal)
 - T3: 3.6 pmol/L (normal)

- T4: 19.05 pmol/L (elevated)
- **Weight Loss:** 50 kg (unintentional, concerning)
- **Ultrasound Thyroid:** No nodules
- **Lymphatic Pain Scores (VAS):**
 - Left axillary: 9
 - Right axillary: 8
 - Left inguinal: 7
 - Right inguinal: 6

CHAMP Intervention Components:

1. **Manual Lymphatic Therapy:**
 - Focused therapy over six months in bilateral axillary and inguinal regions
 - Pain measured using Visual Analog Scale (VAS)
2. **Lifestyle Protocols (ACLM, USA):**
 - Targeted interventions across diet, stress, sleep, physical activity
 - Implemented based on FDA-approved protocols
3. **Diagnostics:**
 - Laboratory testing accredited by the College of American Pathologists (CAP)

Results

Parameter	Pre-CHAMP	Post-CHAMP	Interpretation
CRP (mg/L)	22.2 (High)	3.2 (Significantly reduced)	Inflammation decreased
Homocysteine (μmol/L)	18.0	3.9	Vascular risk reversed
T4 (pmol/L)	19.05	12.5 (Normal)	Thyroid normalization
Body Weight	50 kg	60 kg	Healthy weight gain achieved
Thyroid Ultrasound	No nodules	Normal findings	Consistent and stable outcome

Lymphatic Pain Scores (VAS – Visual Analog Scale):

Region	Before	After
Left Axillary	9	0
Right Axillary	8	0

Region	Before	After
Left Inguinal	7	0
Right Inguinal	6	0

Discussion

The patient's inflammatory and vascular markers demonstrated significant improvements, particularly the normalization of homocysteine and CRP levels. The reduction of lymphatic discomfort to zero across all quadrants confirmed the efficacy of the manual lymphatic therapy provided. Weight gain was a key clinical marker of systemic recovery, particularly in light of the prior unintentional weight loss. The thyroid function stabilized, eliminating concerns of progressing to hyperthyroidism or nodular thyroid disease. Given the familial risk of cancer, this early recovery potentially represents a preventive strategy via systemic detoxification and immune regulation.

This aligns with literature emphasizing the link between chronic inflammation and cancer risk, as well as the effectiveness of lifestyle-based, patient-centric protocols supported by ACLM.

Conclusion

Patient's case illustrates that even with underlying endocrine conditions and a hereditary cancer risk, a six-month non-invasive, integrative programme can lead to substantial clinical improvement. The CHAMP protocol offers an effective and sustainable alternative for improving inflammation, vascular health, pain, and functional wellness.

Keywords:

Thyroiditis, CRP, Homocysteine, weight recovery, lymphatic drainage, manual lymphatic therapy, lifestyle medicine, inflammation, colon cancer risk, CHAMP